Showing 4081-4090 of 5957 results for "".
- NIH: New Technique Enhances Quality Control of Lab-Grown Cells for AMD Treatmenthttps://modernod.com/news/nih-new-technique-enhances-quality-control-of-lab-grown-cells-for-amd-treatment/2482074/Researchers at the National Eye Institute (NEI) say they have improved a crucial step in the production of retinal pigment epithelium (RPE) they are testing in a clinical trial as treatment for age-related macular degeneration (AMD). Their technique combines electrochemical cell measurements
- Mega-Analysis Identifies Gene Variants Associated with Glaucoma in People of African Ancestryhttps://modernod.com/news/mega-analysis-identifies-gene-variants-associated-with-glaucoma-in-people-of-african-ancestry/2482072/A new analysis focusing specifically on people of African ancestry identified three gene variants that may be contributing to this population’s susceptibility to developing and being blinded by glaucoma, according to report from the Perelman School of Medicine at the University of Pennsylva
- Sydnexis Appoints Erin Horn as Vice President, Head of Market Accesshttps://modernod.com/news/sydnexis-names-erin-horn-as-vice-president-head-of-market-access/2482071/Sydnexis has announced the appointment of Erin Horn as Vice President, Head of Market Access. Ms. Horn will lead Sydnexis’ market access, pricing, contracting, and go-to-market strategies. With 25 years of industry experience, Ms. Horn has a track record of commercial success
- iuvo BioScience Acquires Promedica International to Expand Ophthalmic Clinical CRO Serviceshttps://modernod.com/news/iuvo-bioscience-acquires-promedica-international-to-expand-ophthalmic-clinical-cro-services/2482070/Partner Research Organization iuvo BioScience announced it has acquired Promedica International (PMI), an ophthalmology-focused clinical CRO. Financial terms of the deal were not disclosed. The companies say the combined organization will support all aspects of opht
- Inflammasome Therapeutics Announces First Patient Dosed in Phase 1 DME Study of the Dual Inflammasome Inhibitor K8https://modernod.com/news/inflammasome-therapeutics-announces-first-patient-dosed-in-phase-1-dme-study-of-the-dual-inflammasome-inhibitor-k8/2482069/Inflammasome Therapeutics announced the first patient has been dosed in a phase 1 study of a novel compound in the treatment of diabetic macular edema (DME). The 24-week study (ClinicalTrials.gov ID NCT05699759) is designed to assess safety and initial evidence of efficacy. Th
- LumiThera Initiates EUROLIGHT Registry Study to Evaluate Long-Term Benefits of PBM Using the Valeda for Dry AMDhttps://modernod.com/news/lumithera-initiates-eurolight-registry-study-to-evaluate-long-term-benefits-of-pbm-using-the-valeda-light-delivery-system-for-dry-amd/2482067/LumiThera announced the initiation of the largest PBM trial ever conducted in patients with dry age-related macular degeneration (AMD). A global registry data collection from patients treated with PBM using the Valeda Light Delivery System has been established with Dendrite Clinica
- Rayner Acquires This AG, Maker of Sophi Phaco Machineshttps://modernod.com/news/rayner-acquires-this-ag-maker-of-sophi-phaco-machines/2482064/Rayner announced that it has entered into a definitive agreement to acquire Swiss-based This AG, the inventor, developer and manufacturer of Sophi phaco emulsification machines. Financial terms of the deal were not disclosed. The acquisition marks a new chapter for R
- Alcon Announces Positive Topline Results From Phase 3 COMET Trials of AR-15512 for Dry Eye Diseasehttps://modernod.com/news/alcon-announces-positive-topline-results-from-phase-3-comet-trials-of-ar-15512-a-novel-topical-drug-candidate-for-dry-eye/2482063/Alcon announced positive topline results from the two pivotal phase 3 clinical trials (COMET-2 and COMET-3) evaluating the efficacy and safety of AR-15512, a candidate treatment for the signs and symptoms of dry eye disease (DED). In both COMET-2 and COMET-3, which enrolled more than 93
- Aviceda Announces Topline Data From Part 1 of the Phase 2/3 SIGLEC Trial of GA Drug Candidate AVD-104https://modernod.com/news/aviceda-therapeutics-announces-topline-data-from-part-1-of-the-phase-23-siglec-clinical-trial-for-avd-104-demonstrating-positive-safety-and-early-clinical-efficacy-in-patients-with-geographic-atrophy/2482061/Aviceda Therapeutics announced positive topline data of part 1 of the phase 2/3 SIGLEC trial for AVD-104 in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD), showing positive safety and efficacy outcomes which were observed at 3 months after a single
- Aviceda Enrolls First Patient in Phase 2 GLYCO Clinical Trial Evaluating AVD-104 for the Treatment of DMEhttps://modernod.com/news/aviceda-enrolls-first-patient-in-phase-2-glyco-clinical-trial-evaluating-avd-104-for-the-treatment-of-dme/2482058/Aviceda Therapeutics announced that it has enrolled the first patient in the GLYCO phase 2 US clinical trial evaluating its lead ophthalmic candidate AVD-104 for the management of diabetic macular edema (DME). AVD-104 is an engineered glycan (sialic acid) nanoparticle that reduces inflammati